We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Relapse-free rate

MAVENCLAD™ ALLOWED 79.7% OF PATIENTS TO REMAIN RELAPSE-FREE AT 96 WEEKS1

Patients without relapse over 96 weeks (secondary endpoint)*

Relapse-Free

At 96 weeks, 79.7% of patients were relapse-free with MAVENCLAD vs. 60.9% for placebo (p<0.001; OR: 2.53 [95% CI: 1.87-3.43])1,2  

Learn more about MAVENCLAD

 

Demonstrated reduction in ARR

 

Demonstrated reduction in 3-month EDSS progression

Demonstrated reduction in brain lesions

  

 

See how MAVENCLAD achieved
a 57.6% relative reduction in ARR over 96 weeks vs. placebo
(p<0.001, 0.14 vs. 0.33, respectively).   

Learn more

See how MAVENCLAD delivered a 33%
reduction in risk of disability progression (EDSS) vs. placebo (p=0.02, HR: 0.67,
secondary endpoint).

Learn more

Discover how MAVENCLAD
demonstrated an 86% relative
reduction in T1 Gd+ lesions and
73% in T2 lesions over 96 weeks
vs. placebo (p<0.001; mean lesions:
T1 Gd+, 0.12 vs. 0.91; T2,  0.38 vs. 1.43; secondary endpoint).  

Learn more

  
Footnotes and References

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; OR=odds ratio

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1 
 

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.

© 2019 EMD Serono. All rights reserved.
MAVENCLAD™ is a trademark of Merck KGaA, Darmstadt, Germany.

Importer & Distributor:
EMD Serono, A Division of EMD Inc., Canada
A business of Merck KGaA, Darmstadt, Germany
2695 North Sheridan Way, Suite 200
Mississauga, Ontario  L5K 2N6 Canada

If your patients experience any side effects, they should talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in the package insert. Side effects can also be reported directly via the Health Canada website at www.healthcanada.gc.ca/medeffect, by calling the Regional Adverse Reaction Centre at 1-866-234-2345 or by contacting the adveva team at 1-888-677-3243.

CA/CLA/0318/0013E

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our Cookie policy.

OK, GOT IT

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.

lightbox image